All Outputs (31)

Genome-wide association study identifies risk loci for progressive chronic lymphocytic leukemia (2021)
Journal Article
Lin, W. Y., Fordham, S. E., Sunter, N., Elstob, C., Rahman, T., Willmore, E., Shepherd, C., Strathdee, G., Mainou-Fowler, T., Piddock, R., Mearns, H., Barrow, T., Houlston, R. S., Marr, H., Wallis, J., Summerfield, G., Marshall, S., Pettitt, A., Pepper, C., Fegan, C., …Allan, J. M. (2021). Genome-wide association study identifies risk loci for progressive chronic lymphocytic leukemia. Nature communications, 12(1), Article 665. https://doi.org/10.1038/s41467-020-20822-9

© 2021, The Author(s). Prognostication in patients with chronic lymphocytic leukemia (CLL) is challenging due to heterogeneity in clinical course. We hypothesize that constitutional genetic variation affects disease progression and could aid prognost... Read More about Genome-wide association study identifies risk loci for progressive chronic lymphocytic leukemia.

The investigation of lipoxygenases as therapeutic targets in malignant pleural mesothelioma (2019)
Journal Article
Oguh-Olayinka, L., Agarwal, V., Ranatunge, D., Campbell, A., Laufer, S., Cawkwell, L., & Lind, M. J. (2020). The investigation of lipoxygenases as therapeutic targets in malignant pleural mesothelioma. Pathology and Oncology Research, 26(2), 985-995. https://doi.org/10.1007/s12253-019-00652-x

Advanced malignant pleural mesothelioma (MPM) has an extremely poor prognosis with limited chemotherapy options, therefore the identification of new therapeutic targets would aid in disease management. Arachidonic acid is metabolised by cyclooxygenas... Read More about The investigation of lipoxygenases as therapeutic targets in malignant pleural mesothelioma.

Lck is a relevant target in chronic lymphocytic leukaemia cells whose expression variance is unrelated to disease outcome (2017)
Journal Article
Till, K. J., Allen, J. C., Talab, F., Lin, K., Allsup, D., Cawkwell, L., Bentley, A., Ringshausen, I., Duckworth, A. D., Pettitt, A. R., Kalakonda, N., & Slupsky, J. R. (2017). Lck is a relevant target in chronic lymphocytic leukaemia cells whose expression variance is unrelated to disease outcome. Scientific reports, 7(1), Article ARTN 16784. https://doi.org/10.1038/s41598-017-17021-w

© 2017 The Author(s). Pathogenesis of chronic lymphocytic leukaemia (CLL) is contingent upon antigen receptor (BCR) expressed by malignant cells of this disease. Studies on somatic hypermutation of the antigen binding region, receptor expression leve... Read More about Lck is a relevant target in chronic lymphocytic leukaemia cells whose expression variance is unrelated to disease outcome.

EGFR and related therapeutic targets in malignant pleural mesothelioma (2016)
Thesis
Oguh, L. I. (2016). EGFR and related therapeutic targets in malignant pleural mesothelioma. (Thesis). Hull York Medical School, the University of Hull and the University of York. Retrieved from https://hull-repository.worktribe.com/output/4221787

Introduction
Malignant pleural mesothelioma (MPM) is a rare but aggressive disease and the current first line treatment is associated with a survival rate of 40%. There is currently no second line therapy. This study aimed to explore the expression... Read More about EGFR and related therapeutic targets in malignant pleural mesothelioma.

Clinical response to primary letrozole therapy in elderly patients with early breast cancer : possible role for p53 as a biomarker (2014)
Journal Article
Garimella, V., Hussain, T., Agarwal, V., Radhakrishna, S., Fox, J. N., Kneeshaw, P. J., Long, E. D., Mahapatra, T. K., McManus, P. L., Lind, M. J., Drew, P. J., & Cawkwell, L. (2014). Clinical response to primary letrozole therapy in elderly patients with early breast cancer : possible role for p53 as a biomarker. International journal of surgery, 12(8), 821-826. https://doi.org/10.1016/j.ijsu.2014.06.009

Primary tamoxifen therapy has been widely used to treat elderly women with ER-positive breast cancer in the past. Aromatase inhibitors may be more beneficial than tamoxifen when used as primary endocrine therapy in elderly patients. We aimed to retro... Read More about Clinical response to primary letrozole therapy in elderly patients with early breast cancer : possible role for p53 as a biomarker.

Telomere dysfunction accurately predicts clinical outcome in chronic lymphocytic leukaemia, even in patients with early stage disease (2014)
Journal Article
Lin, T. T., Norris, K., Heppel, N. H., Pratt, G., Allan, J. M., Allsup, D. J., Bailey, J., Cawkwell, L., Hills, R., Grimstead, J. W., Jones, R. E., Britt-Compton, B., Fegan, C., Baird, D. M., & Pepper, C. (2014). Telomere dysfunction accurately predicts clinical outcome in chronic lymphocytic leukaemia, even in patients with early stage disease. British journal of haematology, 167(2), 214-223. https://doi.org/10.1111/bjh.13023

© 2014 John Wiley & Sons Ltd. Defining the prognosis of individual cancer sufferers remains a significant clinical challenge. Here we assessed the ability of high-resolution single telomere length analysis (STELA), combined with an experimentally d... Read More about Telomere dysfunction accurately predicts clinical outcome in chronic lymphocytic leukaemia, even in patients with early stage disease.

The role of the Kinin-Kallikrein System in chronic lymphocytic leukaemia (2014)
Thesis
Kashuba, E. (2014). The role of the Kinin-Kallikrein System in chronic lymphocytic leukaemia. (Thesis). Hull York Medical School, the University of Hull and the University of York. Retrieved from https://hull-repository.worktribe.com/output/4216406

Background:
Chronic lymphocytic leukaemia (CLL) is an incurable heterogeneous disease. The identification of reliable and cost effective biomarkers is therefore imperative. A comparative proteomic approach was previously employed to study protein ex... Read More about The role of the Kinin-Kallikrein System in chronic lymphocytic leukaemia.

Identification of predictive biomarkers of resistance to radiotherapy in rectal cancer (2013)
Thesis
Mehmood, S. (2013). Identification of predictive biomarkers of resistance to radiotherapy in rectal cancer. (Thesis). University of Hull. Retrieved from https://hull-repository.worktribe.com/output/4216079

Introduction and Aims:
Neoadjuvant radiotherapy (RT) provides local control of disease in rectal cancer, however, the ability to predict response to RT is limited. The aim of this study was to establish a novel radioresistant (RR) rectal cancer cell... Read More about Identification of predictive biomarkers of resistance to radiotherapy in rectal cancer.

Proteomic analysis of B-cell receptor signaling in chronic lymphocytic leukaemia reveals a possible role for kininogen (2013)
Journal Article
Kashuba, E., Eagle, G. L., Bailey, J., Evans, P., Welham, K. J., Allsup, D., & Cawkwell, L. (2013). Proteomic analysis of B-cell receptor signaling in chronic lymphocytic leukaemia reveals a possible role for kininogen. Journal of Proteomics, 91, 478-485. https://doi.org/10.1016/j.jprot.2013.08.002

CLL is an incurable disease with variable prognosis. The hyper reactivity of the B-cell receptor (BCR) to unknown antigen ligation plays a pivotal role in CLL-cell survival. We aimed to investigate the BCR signalling pathway using proteomics to ident... Read More about Proteomic analysis of B-cell receptor signaling in chronic lymphocytic leukaemia reveals a possible role for kininogen.

The kinin–kallikrein system: physiological roles, pathophysiology and its relationship to cancer biomarkers (2013)
Journal Article
Kashuba, E., Bailey, J., Allsup, D., & Cawkwell, L. (2013). The kinin–kallikrein system: physiological roles, pathophysiology and its relationship to cancer biomarkers. Biomarkers, 18(4), 279-296. https://doi.org/10.3109/1354750x.2013.787544

The kinin–kallikrein system (KKS) is an endogenous multiprotein cascade, the activation of which leads to triggering of the intrinsic coagulation pathway and enzymatic hydrolysis of kininogens with the consequent release of bradykinin-related peptide... Read More about The kinin–kallikrein system: physiological roles, pathophysiology and its relationship to cancer biomarkers.

Proteomic (antibody microarray) exploration of the molecular mechanism of action of the specific COX-2 inhibitor DuP 697 (2013)
Journal Article
Agarwal, V., Hodgkinson, V. C., Eagle, G. L., Scaife, L., Lind, M. J., & Cawkwell, L. (2013). Proteomic (antibody microarray) exploration of the molecular mechanism of action of the specific COX-2 inhibitor DuP 697. International Journal of Oncology, 42(3), 1088-1092. https://doi.org/10.3892/ijo.2013.1784

We have previously shown that specific COX-2 inhibitors, including DuP 697, have anti-proliferative effects on mesothelioma cells and potentiate the cytotoxicity of pemetrexed. Here, we used a novel proteomic approach to explore the mechanism of acti... Read More about Proteomic (antibody microarray) exploration of the molecular mechanism of action of the specific COX-2 inhibitor DuP 697.

PTEN protein expression in malignant pleural mesothelioma (2012)
Journal Article
Agarwal, V., Campbell, A., Beaumont, K. L., Cawkwell, L., & Lind, M. J. (2013). PTEN protein expression in malignant pleural mesothelioma. Tumor Biology, 34(2), 847-851. https://doi.org/10.1007/s13277-012-0615-9

Malignant pleural mesothelioma is associated with poor prognosis and despite recent advances in chemotherapy, the median survival is still approximately 12 months. Loss of phosphatase and tensin homolog (PTEN) protein expression may lead to constitut... Read More about PTEN protein expression in malignant pleural mesothelioma.

Proteomic identification and validation of biomarkers associated with resistance to radiotherapy in breast cancer (2012)
Thesis
ElFadl, D. (2012). Proteomic identification and validation of biomarkers associated with resistance to radiotherapy in breast cancer. (Thesis). University of Hull. Retrieved from https://hull-repository.worktribe.com/output/4218629

Background:
Breast cancer is an important health issue. The majority of patients present with early stage cancer and are therefore candidates for breast conserving surgery and radiotherapy. A proportion will suffer from local recurrence, which may b... Read More about Proteomic identification and validation of biomarkers associated with resistance to radiotherapy in breast cancer.

Proteomic identification of putative biomarkers of radiotherapy resistance (2012)
Thesis
Scaife, L. (2012). Proteomic identification of putative biomarkers of radiotherapy resistance. (Thesis). University of Hull. Retrieved from https://hull-repository.worktribe.com/output/4214086

Background
Currently, tumour response to radiotherapy cannot be predicted meaning that those patients with tumours resistant to the therapy endure the harmful side effects associated with ionising radiation in the absence of therapeutic gain. The ai... Read More about Proteomic identification of putative biomarkers of radiotherapy resistance.

Pilot and feasibility study: comparative proteomic analysis by 2-DE MALDI TOF/TOF MS reveals 14-3-3 proteins as putative biomarkers of response to neoadjuvant chemotherapy in ER-positive breast cancer (2012)
Journal Article
Hodgkinson, V. C., Agarwal, V., ElFadl, D., Fox, J. N., McManus, P. L., Mahapatra, T. K., Kneeshaw, P. J., Drew, P. J., Lind, M., & Cawkwell, L. (2012). Pilot and feasibility study: comparative proteomic analysis by 2-DE MALDI TOF/TOF MS reveals 14-3-3 proteins as putative biomarkers of response to neoadjuvant chemotherapy in ER-positive breast cancer. Journal of Proteomics, 75(9), 2745-2752. https://doi.org/10.1016/j.jprot.2012.03.049

Neoadjuvant chemotherapy is used to treat oestrogen receptor-positive breast cancer however chemo-resistance is a major obstacle in this molecular subtype. The ability to predict tumour response would allow chemotherapy administration to be directed... Read More about Pilot and feasibility study: comparative proteomic analysis by 2-DE MALDI TOF/TOF MS reveals 14-3-3 proteins as putative biomarkers of response to neoadjuvant chemotherapy in ER-positive breast cancer.

The significance of the EGFR pathway in malignant pleural mesothelioma (2012)
Thesis
Agarwal, V. (. (2012). The significance of the EGFR pathway in malignant pleural mesothelioma. (Thesis). Hull York Medical School, the University of Hull and the University of York. Retrieved from https://hull-repository.worktribe.com/output/4214047

Introduction
EGFR, MTOR and COX2 are up regulated in malignant pleural mesothelioma (MPM). In this study we aimed to determine the expression of Lipoxygenase enzymes (LOX), absence of PTEN protein expression and the cytotoxic effect of EGFR, MTOR an... Read More about The significance of the EGFR pathway in malignant pleural mesothelioma.

Proteomic identification of predictive biomarkers of resistance to neoadjuvant chemotherapy in luminal breast cancer: a possible role for 14-3-3 theta/tau and tBID? (2012)
Journal Article
Hodgkinson, V. C., ELFadl, D., Agarwal, V., Garimella, V., Russell, C., Long, E. D., Fox, J. N., McManus, P. L., Mahapatra, T. K., Kneeshaw, P. J., Drew, P. J., Lind, M. J., & Cawkwell, L. (2012). Proteomic identification of predictive biomarkers of resistance to neoadjuvant chemotherapy in luminal breast cancer: a possible role for 14-3-3 theta/tau and tBID?. Journal of Proteomics, 75(4), 1276-1283. https://doi.org/10.1016/j.jprot.2011.11.005

Introduction: Chemotherapy resistance is a major obstacle in effective neoadjuvant treatment for estrogen receptor-positive breast cancer. The ability to predict tumour response would allow chemotherapy administration to be directed towards only thos... Read More about Proteomic identification of predictive biomarkers of resistance to neoadjuvant chemotherapy in luminal breast cancer: a possible role for 14-3-3 theta/tau and tBID?.

The identification of biomarkers of chemotherapy resistance in breast cancer using comparative proteomics (2011)
Thesis
Hodgkinson, V. C. (2011). The identification of biomarkers of chemotherapy resistance in breast cancer using comparative proteomics. (Thesis). University of Hull. Retrieved from https://hull-repository.worktribe.com/output/4211852

Background:Chemotherapy resistance is a major obstacle in effective neoadjuvant treatment for locally advanced breast cancer. The ability to predict tumour response would allow chemotherapy administration to be directed towards only those patients wh... Read More about The identification of biomarkers of chemotherapy resistance in breast cancer using comparative proteomics.

Differential proteomics in the search for biomarkers of radiotherapy resistance (2011)
Journal Article
Scaife, L., Hodgkinson, V. C., Drew, P. J., Lind, M. J., & Cawkwell, L. (2011). Differential proteomics in the search for biomarkers of radiotherapy resistance. Expert Review of Proteomics, 8(4), 535-552. https://doi.org/10.1586/EPR.11.32

The individualization of radiotherapy treatment would be beneficial for cancer patients; however, there are no predictive biomarkers of radiotherapy resistance in routine clinical use. This article describes the body of work in this field where compa... Read More about Differential proteomics in the search for biomarkers of radiotherapy resistance.

Novel anti-endothelial therapeutic strategies in malignant melanoma : the metronomic approach. (2011)
Thesis
Murray, A. M. (2011). Novel anti-endothelial therapeutic strategies in malignant melanoma : the metronomic approach. (Thesis). University of Hull. Retrieved from https://hull-repository.worktribe.com/output/4211876

Treatment strategies for advanced malignancy remain limited in their success, despite major advances in the understanding of cancer aetiology and molecular biology. The incidence of many cancers, including melanoma, continues to rise, with a huge dem... Read More about Novel anti-endothelial therapeutic strategies in malignant melanoma : the metronomic approach..